CDC42BPA and benign prostatic hyperplasia: Moreover, Rho effector kinases such as myotonic dystrophy kinase-related cdc42-binding kinases α (MRCKα) also possess synthetic lethal in E-cadherin defective cells, which showed potential to treat E-cadherin deficient diseases, such as BPH [136].